24
FEATURE:
CELGENE
"Generics will not exist if we don't invest in branded, innovative
therapies that get fully protected for the life of the intellectual
property," says Bob Hugin, chairman and CEO of Celgene.
April 2013
CONTENTS
Welcome to
Life Science Leader
30
36
40
GSK AND
VENTURE CAPITAL
BIOSIMILAR
REGULATIONS
THE PHARMA
COLD CHAIN
How Pfizer is navigating the everchanging biosimilar regulations
Some valuable tips and insights
about cold chain packaging and
processes
A candid conversation with Jens
Eckstein, president of GSK's SR One
VC fund
4
LifeScienceLeader.com
April 2013
DEPARTMENTS
6 Editor's Note
8 Editorial Board/Ask The Board
10 Capitol Perspectives
14 Companies To Watch
16 Outsourcing Insights
20 Bio Innovation Notes
44 Pharma Supply Chain
48 Contract Sourcing
52 Regulatory Compliance/FDA
54 Pharma Management
58 Pharma Management
62 Global Update
68 Industry Leader
70 Industry Leader
74 Leadership Lessons
Follow LSL on:
at twitter.com/RFWrightLSL
and